Patentability of Chemical Selection Inventions: The Olanzapine and Escitalopram Decisions
The thesis is a response to the recent decisions of the German Federal Court of Justice on the patentability requirements of selection inventions, namely, the Olanzapine and Escitalopram decisions.
Enregistré dans:
Auteur principal: | Ahn, Hyewon (auth) |
---|---|
Format: | Électronique Chapitre de livre |
Langue: | anglais |
Publié: |
Nomos Verlagsgesellschaft mbH & Co. KG
2011
|
Collection: | Munich Intellectual Property Law Center - MIPLC
|
Sujets: | |
Accès en ligne: | DOAB: download the publication DOAB: description of the publication |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Patentability Requirements for Nanotechnological Inventions An Approach from the European Patent Convention Perspective
par: Cisneros, Mario
Publié: (2009) -
Second Generation Patents in Pharmaceutical Innovation
par: Ahn, Hyewon
Publié: (2014) -
Bioethics and the Patent Eligibility of Human Embryonic Stem Cells-Related Inventions in Europe
par: Ugurlu, Ali Seyhan
Publié: (2014) -
Patent Strategy in Pharmaceutical Industry: Are additional patents valuable?
par: Donghi, Monica
Publié: (2014) -
Patenting Proteomics Patentability and Scope of Protection of Three-Dimensional Protein Structure Claims under German, European and US law
par: Schuster, Martina
Publié: (2010)